{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:20:55Z","timestamp":1782926455452,"version":"3.54.5"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"am","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.canrad.2020.06.037","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T02:39:39Z","timestamp":1616553579000},"page":"424-431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Association du double blocage de HER2\u00a0et radioth\u00e9rapie dans la prise en charge du cancer du sein exprimant HER2"],"prefix":"10.1016","volume":"25","author":[{"given":"S.","family":"Ben Dhia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8863-8110","authenticated-orcid":false,"given":"P.","family":"Loap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Loirat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vincent-Salomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2475-1821","authenticated-orcid":false,"given":"K.","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Escalup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fourquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Kirova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2020.06.037_bib0180","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/BCTT.S176070","article-title":"Epidemiological characteristics of and risk factors for breast cancer in the world","volume":"11","author":"Momeni Movahed","year":"2019","journal-title":"Breast Cancer Targets Ther"},{"key":"10.1016\/j.canrad.2020.06.037_bib0185","doi-asserted-by":"crossref","first-page":"7350","DOI":"10.1200\/JCO.2005.03.3845","article-title":"Molecular classification and molecular forecasting of breast cancer: ready for clinical application?","volume":"23","author":"Brenton","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2020.06.037_bib0190","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.radonc.2017.07.006","article-title":"Concurrent administration of anti-HER2\u00a0therapy and radiotherapy: systematic review","volume":"124","author":"Mignot","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2020.06.037_bib0195","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10549-014-3166-5","article-title":"Concurrent administration of trastuzumab with locoregional breast radiotherapy: long-term results of a prospective study","volume":"148","author":"Jacob","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.canrad.2020.06.037_bib0200","first-page":"8","article-title":"p185HER2\u00a0monoclonal antibody has an iproliferative effects in vitro and sensitises human breast tumour cells to tumour necrosis factor","volume":"9","author":"Hudziak","year":"1989","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.canrad.2020.06.037_bib0205","article-title":"Trastuzumab containing regimens for early breast cancer","author":"Moja","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.canrad.2020.06.037_bib0210","article-title":"Trastuzumab-containing regimens for metastatic breast cancer","author":"Balduzzi","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.canrad.2020.06.037_bib0215","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1158\/1078-0432.CCR-14-1268","article-title":"First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer","volume":"20","author":"Amiri-Kordestani","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canrad.2020.06.037_bib0220","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ctrv.2013.09.002","article-title":"A systematic review of dual targeting in HER2-positive breast cancer","volume":"40","author":"K\u00fcmler","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.canrad.2020.06.037_bib0225","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double blind, placebo-controlled, phase 3\u00a0study","volume":"14","author":"Swain","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2020.06.037_bib0230","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.meddos.2011.03.002","article-title":"Simplified field-in-field technique for a large-scale implementation in breast radiation treatment","volume":"37","author":"Fournier-Bidoz","year":"2012","journal-title":"Med Dosim"},{"key":"10.1016\/j.canrad.2020.06.037_bib0235","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.radonc.2013.10.038","article-title":"Whole breast radiotherapy in the lateral decubitus position: a dosimetric and clinical solution to decrease the doses to the organs at risk (OAR)","volume":"110","author":"Kirova","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2020.06.037_bib0240","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.ijrobp.2007.05.007","article-title":"Postmastectomy electron beam chest wall irradiation in women with breast cancer: a clinical step toward conformal electron therapy","volume":"69","author":"Kirova","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2020.06.037_bib0245","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ijrobp.2007.12.059","article-title":"How to boost the breast tumour bed? A multidisciplinary approach in eight steps","volume":"72","author":"Kirova","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2020.06.037_bib0250","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.canrad.2020.06.037_bib0255","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1093\/annonc\/12.suppl_1.S57","article-title":"Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data","volume":"12","author":"Eiermann","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2020.06.037_bib0260","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11\u00a0years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.canrad.2020.06.037_bib0265","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2020.06.037_bib0270","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","article-title":"Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 \u2013 positive breast cancer: planned joint analysis of overall survival from NSABP B-31\u00a0and NCCTG N9831","volume":"32","author":"Perez","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2020.06.037_bib0275","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2020.06.037_bib0280","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","article-title":"Cancer drugs and the heart: importance and management","volume":"34","author":"Suter","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.canrad.2020.06.037_bib0290","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","article-title":"Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer treatment group N9831\u00a0adjuvant breast cancer trial","volume":"26","author":"Perez","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2020.06.037_bib0295","doi-asserted-by":"crossref","first-page":"e1002989","DOI":"10.1371\/journal.pmed.1002989","article-title":"Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study","volume":"16","author":"Kabor\u00e9","year":"2019","journal-title":"PLOS Med"},{"key":"10.1016\/j.canrad.2020.06.037_bib0300","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S1470-2045(13)70225-0","article-title":"6\u00a0months versus 12\u00a0months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3\u00a0trial","volume":"14","author":"Pivot","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2020.06.037_bib0285","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1200\/JCO.2009.23.6950","volume":"28","author":"Russell","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2020.06.037_bib0305","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2020.06.037_bib0310","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2004.08.066","article-title":"Inhibition of ErbB2\u00a0causes mitochondrial dysfunction in cardiomyocytes","volume":"44","author":"Grazette","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.canrad.2020.06.037_bib0315","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2\u00a0randomised trial","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2020.06.037_bib0320","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomised phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2020.06.037_bib0325","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2020.06.037_bib0330","volume":"4","author":"Antonio","year":"2019"},{"key":"10.1016\/j.canrad.2020.06.037_bib0335","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.radonc.2019.12.019","article-title":"Radiation therapy to the primary tumour for de novo metastatic breast cancer and overall survival in a retrospective multicentre cohort analysis","volume":"145","author":"Pons-Tostivint","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2020.06.037_bib0340","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1245\/s10434-018-6831-9","article-title":"Survival impact of locoregional treatment of the primary tumour in de novo metastatic breast cancers in a large multicentric cohort study: a propensity score-matched analysis","volume":"26","author":"Pons-Tostivint","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.canrad.2020.06.037_bib0345","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/j.prro.2014.06.006","article-title":"Radiosensitising effect of anti-HER2\/neu agents: report of 2\u00a0cases and review of the literature","volume":"5","author":"Katz","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2020.06.037_bib0175","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.canrad.2016.10.002","article-title":"Combination of radiotherapy and double blockade HER2\u00a0with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and\/or metastatic breast cancer: assessment of early toxicity","volume":"21","author":"Ajgal","year":"2017","journal-title":"Cancer Radiother"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321820303371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321820303371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:33:08Z","timestamp":1761136388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321820303371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1278321820303371"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2020.06.037","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association du double blocage de HER2\u00a0et radioth\u00e9rapie dans la prise en charge du cancer du sein exprimant HER2","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2020.06.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}